CLN3-related Disorders, Non-CLN3 Related Low Vision
Conditions
Keywords
OrCam, Legal blindness, Safety, Feasibility, Efficacy
Brief summary
Background: CLN3 involves vision loss observed around the preschool years, with eventual progression to blindness within 1-3 years. Researchers want to test an assistive device that may help children with CLN3 or with non-CLN3 related blindness. Objective: To learn if it is safe, easy, and useful for children with CLN3 or with non-CLN3 related blindness to use the OrCam. Eligibility: People aged 6-18 years who have either CLN3-related disease or non-CLN3 related blindness. Design: Participants will be screened with the following: Medical history Physical exam Family history Eye exam and vision tests. They will get eyedrops to dilate their eyes. Psychological and neurocognitive tests. They will be asked questions and observed for how they do various tasks, such as talking, playing, writing, drawing, and solving problems. Hearing tests. They may wear headphones or earplugs. Electrodes may be taped to their head. Blood samples Skin biopsy, if needed Cheek cell, saliva, or urine samples The OrCam is the size of and weighs about half as much as a pack of gum. It is attached to eyeglass frames by magnets. Participants will do tasks before and after they have been trained on the OrCam. They will do these tasks without or with using the OrCam. Participants will be given an OrCam to use for 1 week or 1 month. They will have check-in sessions with the study team. Participants and/or their caregivers will be asked about abilities, behaviors, social skills, learning methods, intelligence, and health-related quality of life. Participants samples may be used for genetic testing and/or to make a type of stem cell. Participation will last for 1-5 weeks.
Detailed description
Study Description: This is a pilot study of an augmentative visual device, OrCam MyEye 2 (OrCam), in pediatric individuals with CLN3-related conditions or low vision. We hypothesize that, given the relatively simple design and operating procedure of the device, the use of the OrCam by study participants will be safe and feasible. We also hypothesize that the device will enhance their ability to obtain visually based information. Objectives: Primary: Assess the safety and feasibility of OrCam use by children with CLN3 or low vision. Endpoints: Primary: 1. Adverse events during the use of OrCam 2. Feasibility test 3. Feasibility questionnaire The assessment periods will be 1 week at study site.
Interventions
DEVICEOrCam MyEye 2
The OrCam MyEye 2 is a 22.5-g portable, eyeglass-mounted device that converts camera-captured inputs to auditory outputs. Its advertised functions include text reading, facial recognition, and product identification.
Sponsors
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DEVICE_FEASIBILITY
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
6 Years to 18 Years
Healthy volunteers
No
Inclusion criteria
To participate in the screening portion of this study, an individual must meet all of the following criteria: 1. Have a diagnosis or suspected diagnosis of any genetically based condition causing low vision to the level specified in criteria 2. If the genetic condition is CLN3-related, the individual must have one of the following: * a. Two CLN3 pathogenic variants, OR * b. One CLN3 pathogenic variant AND * i. clinical presentation suggestive of CLN3, OR * ii. characteristic electron microscopy (EM) findings (such as curvilinear body, fingerprint profile, granular osmiophilic deposits). 2. Have an estimated visual acuity in the better seeing eye \< 20/200, without the use of an assistive or augmentative device. 3. Is between 6 to 18 years of age. To participate in the intervention/device use portion of this study, an individual must meet the above screening criteria and the following criteria: * Have an appropriate cognitive developmental ability to participate based on Investigators screening assessment.
Exclusion criteria
An individual who meets any of the following criteria will be excluded from participation in this study: * Has any of the following auditory dysfunctions: non-reversible or non-correctable hearing loss, tinnitus that is chronic or occurring daily, auditory hallucinations that occur daily. * Uses an optic-to-audio assistive device at the time or within 3 months of screening and enrollment. * Is unable to travel to the NIH because of medical condition for required in-person portions of the study. * Is unable to comply with or have medical conditions that would potentially increase the risk of participation.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Participants With Adverse Events | 1 week | Number of participants with adverse events related to the use of OrCam MyEye 2. Adverse events were collected from parental report. |
Countries
United States
Participant flow
Pre-assignment details
Of 11 participants consented for the study, one participant was a screen failure
Participants by arm
| Arm | Count |
|---|---|
| Children With CLN3 Disease Children with CLN3 use the OrCam MyEye 2, a 22.5-g portable, eyeglass-mounted device that converts camera-captured inputs to auditory outputs for text reading, facial recognition, and product identification. The study participants and parents/guardians were trained on how to use the device. | 9 |
| Children With Low Vision Without CLN3 Children with low vision not related to CLN3 use the OrCam MyEye 2, a 22.5-g portable, eyeglass-mounted device that converts camera-captured inputs to auditory outputs for text reading, facial recognition, and product identification. The study participants and parents/guardians were trained on how to use the device. | 1 |
| Total | 10 |
Baseline characteristics
| Characteristic | Children With CLN3 Disease | Children With Low Vision Without CLN3 | Total |
|---|---|---|---|
| Age, Categorical <=18 years | 9 Participants | 1 Participants | 10 Participants |
| Age, Categorical >=65 years | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical Between 18 and 65 years | 0 Participants | 0 Participants | 0 Participants |
| Ethnicity (NIH/OMB) Hispanic or Latino | 3 Participants | 0 Participants | 3 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 6 Participants | 1 Participants | 7 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 2 Participants | 0 Participants | 2 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 2 Participants | 0 Participants | 2 Participants |
| Race (NIH/OMB) White | 5 Participants | 1 Participants | 6 Participants |
| Region of Enrollment United States | 9 participants | 1 participants | 10 participants |
| Sex: Female, Male Female | 2 Participants | 0 Participants | 2 Participants |
| Sex: Female, Male Male | 7 Participants | 1 Participants | 8 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 0 / 9 | 0 / 1 |
| other Total, other adverse events | 1 / 9 | 0 / 1 |
| serious Total, serious adverse events | 0 / 9 | 0 / 1 |
Outcome results
Primary
Participants With Adverse Events
Number of participants with adverse events related to the use of OrCam MyEye 2. Adverse events were collected from parental report.
Time frame: 1 week
Population: All participants who completed week one of the study.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Children With CLN3 Disease | Participants With Adverse Events | 1 Participants |
| Children With Low Vision Without CLN3 | Participants With Adverse Events | 0 Participants |